Total laparoscopic radical hysterectomy for treatment of uterine malignant tumors: Analysis of short-term therapeutic efficacy

Abstract

To investigate the efficacy and the clinical value of total laparoscopic radical hysterectomy (TLRH) for the treatment of uterine malignancies, we performed a retrospective review of 87 patients with cervical cancer and 23 patients with endometrial carcinoma who underwent TLRH at Union hospital between June 2008 and September 2009. Data collected included operative time, estimated blood loss, lymph node count, time for the recovery of normal temperature and time to resumption of normal bladder function, intraoperative and postoperative complications. The procedure was completed laparoscopically in 108 patients. Two patients were converted to laparotomy due to common iliac vein injury. The mean overall operative time was 200.6+/-38.6 min; the mean operative blood loss was 280.5+/-128.3 mL; he mean number of pelvic lymph nodes that were resected wa26. 0+/-5.8. The time for recovery of normal temperature and the normal bladder function after the operation was 5.8+/-2.9 d and 15.2+/-4.3 d. There were 2 (1.8%) common iliac vein injuries during the operation and 10 (9.1%) bladder retentions post operation. It was concluded that TLRH is feasible, minimally invasive and provides promise for the treatment of uterine malignancies.

Laparoscopic procedure compared with open radical hysterectomy with pelvic lymphadenectomy in early cervical cancer: a retrospective study

“…The technique of LRH has been described previously. 20 , 21 A harmonic scalpel was the main instrument for the dissection, division, and maintenance of hemostasis of all major surgical pedicles in the Obstetrics and Gynecology Department, and LRH was performed according to the C2 type of the Querleu–Morrow classification. 22 …”

Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy

“…A total of 19 patients (average age 42.5, range 29-62) with bulky cervical cancer who were treated with NAC (paclitaxel combined with carboplatin systemic chemotherapy and cervical local injection of cisplatin) between Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy Following administration of chemotherapy, laparoscopic radical hysterectomy and pelvic lymphadenectomy were performed. The specific surgical procedures are available in our previous reports (7). For the patients with lymph node metastasis, parametrial involvement or positive vaginal margin after surgery, adjuvant radiotherapy was carried out.…”